Breast-conservation Therapy after Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer specific Mortality

Renee L. Arlow, Lisa E. Paddock, Xiaoling Niu, Laurie Kirstein, Bruce G. Haffty, Sharad Goyal, Thomas Kearney, Deborah Toppmeyer, Antoinette M. Stroup, Atif J. Khan

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objectives: Neoadjuvant chemotherapy can increase the rate of breastconserving surgery by downstaging disease in patients with breast cancer. The aim of this study was to determine whether patients who received neoadjuvant chemotherapy have equal survival after breastconservation therapy compared with mastectomy. Material and Methods: Using the New Jersey State Cancer Registry (NJSCR) patients with a primary breast cancer diagnosed between 1998 and 2003 who underwent neoadjuvant chemotherapy were selected (n=1,468). Of those, only patients who received lumpectomy plus radiation (n=276) or mastectomy without radiation (n= 442) were included in the analysis. The main outcome measured included 10-year breast cancer specific mortality, with 90% of patients with known vital status through the end of 2011. Results: Baseline characteristics did not differ significantly between the breast-conservation and mastectomy without radiation groups except with respect to summary stage and lymph node involvement. After propensity score matching these differences were no longer statistically significant; however, both estrogen and progesterone status achieved statistical significance. The Kaplan-Meier survival curve showed that the breast-conservation group had significantly higher breast cancer specific survival than the mastectomy group (P=0.0046). After adjusting for the propensity score in the regression model, the breastconservation group continued to show significantly better survival than the mastectomy group (hazard ratios, 0.46; 95% confidence interval, 0.27-0.78). Conclusions: This study is consistent with previous research showing that breast-conserving surgery after neoadjuvant chemotherapy does not reduce breast cancer specific survival. In fact, patients undergoing breast-conservation after neoadjuvant therapy appeared to have better survival than patients undergoing mastectomy without radiation.

Original languageEnglish (US)
Pages (from-to)1246-1251
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number12
StatePublished - Dec 1 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • breast cancer
  • breast-conservation therapy
  • downstage
  • neoadjuvant chemotherapy

Fingerprint Dive into the research topics of 'Breast-conservation Therapy after Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer specific Mortality'. Together they form a unique fingerprint.

Cite this